Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation
- 1 August 2021
- Vol. 39 (35) , 5055-5063
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Council of State and Territorial Epidemiologists
- Georgia Department of Public Health
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK111024-05S1)
- Centers for Disease Control and Prevention
- National Institutes of Health
- Georgia Institute of Technology
This publication has 17 references indexed in Scilit:
- Prevalence of Asymptomatic SARS-CoV-2 InfectionAnnals of Internal Medicine, 2020
- The COVID-19 Serology Studies Workshop: Recommendations and ChallengesImmunity, 2020
- Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United StatesHealth Affairs, 2020
- Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease PatientsEmerging Infectious Diseases, 2020
- Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020JAMA, 2020
- Mapping county-level mobility pattern changes in the United States in response to COVID-19SIGSPATIAL Special, 2020
- Modeling shield immunity to reduce COVID-19 epidemic spreadNature Medicine, 2020
- Serology Testing for SARS-CoV-2: Benefits and ChallengesIranian Journal of Pathology, 2020
- Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, ChinaJAMA Network Open, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020